Search

everythinglearnresearchcommunity

for

Search:↓

Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

PRP treatment increased hair density, especially in men and younger patients with AGA.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

The 0.05% dutasteride topical solution effectively promotes hair growth with fewer side effects than oral treatments.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

GT20029 helps regrow hair in men with hair loss and is well-tolerated.

Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.

The treatment showed promising hair regrowth in advanced-stage hair loss.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Severe alopecia areata patients have a low chance of spontaneous hair regrowth.

Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.